

Respected Editor-in-Chief,

Kindly note that the IRB approved a waiver for obtaining informed consent for our study as outlined in IRB #2022-035 in the below attachment. Kindly refer to the IRB document for details.

Re: IRB#2022-035: Assessment of the Association of Inflammatory Markers and Hyperglycemia in COvid-19 Patients without Diabetes Mellitus

Dates: 07/01/2021 to 03/30/2022

Jurisdiction: Saint Vincent Medical Center, 123 Summer Street, Worcester, MA 01608

- A waiver of documentation of consent was approved in accordance with 45 CFR 46.117(c).
- The following must be promptly reported to the IRB: changes to the study site, and all unanticipated problems that may involve risks or affect the safety or welfare of subjects or others, or that may affect the integrity of the research.
- Approval is valid for enrollment of the number of subjects indicated on your submission form.
- Advertisements, letters, internet postings and any other media for subject recruitment must be submitted to the IRB and approved prior to use.
- All publications and communications related to this research are subject to Tenet Policy AD 2.16 related to the substantiation of all data/claims with reliable scientific evidence.
- Compliance with all federal and state laws pertaining to this research

If data is collected or shared with another institution/facility a data use agreement must be in place

If you have any questions regarding this determination, please feel free to contact me at mary.oster@mwmc.com or 508-383-8786.

Sincerely,



Mary Oster
IRB Administrator

Sincerely,
Yuvaraj Singh